Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ImpediMed Takes Aim At $1.5B Market With US Launch Of L-Dex For Assessing Lymphedema In Cancer Survivors

Executive Summary

In January, ImpediMed began a national launch of L-Dex, a bioimpedance spectroscopy device designed to allow early detection and treatment of secondary lymphedema, a condition caused by cancer treatment that affects about 900,000 US patients each year – a market estimated at $1.5 billion. Early detection and treatment can greatly reduce or even reverse progression of the disease, and the company is also investigating potential applications in heart failure, a much larger market.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT035984

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel